select trial semaglutide cardiovascular outcomes non-diabetic 2023 Long-term weight loss effects of in obesity without diabetes in the AHA 23 Late-Breaker Discussion: The

While clinical trials show patients losing between 15% and 22% of their body weight on these medications, the most meaningful results are often the "non-scale victories," like having the stamina to play with your children or feeling comfortable in your favorite clothes again

L-carnitine and coenzyme Q10 protective action against ischaemia and reperfusion of [PMID: 1306156] Laboratory literature summary: L-carnitine and coenzyme Q10 protective action against ischaemia and reperfusion of working rat heart

Starting dose phase (2.5mg) The initial 2.5mg dose produces the least gastric emptying delay but is often when you first notice GI side effects

Store in a cool and dry place away from sunlight

This is the strongest single-agent obesity drug currently approved

Benefits Reduces fat and improves metabolic health Supports testosterone indirectly Improves energy and vitality Dose: Start at 0.6 mg daily, titrate up to 1.8 mg, subcutaneous